Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
RARRES3 Antibody (Center) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
| Primary Accession | Q9UL19 |
|---|---|
| Clone Names | 100623024 |
| Gene ID | 5920 |
|---|---|
| Other Names | Retinoic acid receptor responder protein 3, 311-, HRAS-like suppressor 4, HRSL4, RAR-responsive protein TIG3, Retinoid-inducible gene 1 protein, Tazarotene-induced gene 3 protein, RARRES3, RIG1, TIG3 |
| Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
| Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
| Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
| Name | PLAAT4 (HGNC:9869) |
|---|---|
| Synonyms | RARRES3, RIG1, TIG3 |
| Function | Exhibits both phospholipase A1/2 and acyltransferase activities (PubMed:19615464, PubMed:22605381, PubMed:22825852, PubMed:26503625). Shows phospholipase A1 (PLA1) and A2 (PLA2), catalyzing the calcium-independent release of fatty acids from the sn-1 or sn-2 position of glycerophospholipids (PubMed:19615464, PubMed:22605381, PubMed:22825852). For most substrates, PLA1 activity is much higher than PLA2 activity (PubMed:19615464). Shows O- acyltransferase activity, catalyzing the transfer of a fatty acyl group from glycerophospholipid to the hydroxyl group of lysophospholipid (PubMed:19615464). Shows N-acyltransferase activity, catalyzing the calcium-independent transfer of a fatty acyl group at the sn-1 position of phosphatidylcholine (PC) and other glycerophospholipids to the primary amine of phosphatidylethanolamine (PE), forming N- acylphosphatidylethanolamine (NAPE), which serves as precursor for N- acylethanolamines (NAEs) (PubMed:19615464, PubMed:22605381, PubMed:22825852). Promotes keratinocyte differentiation via activation of TGM1 (PubMed:17762858). |
| Cellular Location | Membrane; Single- pass membrane protein |
| Tissue Location | Widely expressed. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Retinoids exert biologic effects such as potent growthinhibitory and cell differentiation activities and are used in thetreatment of hyperproliferative dermatological diseases. Theseeffects are mediated by specific nuclear receptor proteins that aremembers of the steroid and thyroid hormone receptor superfamily oftranscriptional regulators. RARRES1, RARRES2, and RARRES3 are geneswhose expression is upregulated by the synthetic retinoidtazarotene. RARRES3 is thought act as a tumor suppressor or growthregulator.
References
Silva, L.K., et al. Eur. J. Hum. Genet. 18(11):1221-1227(2010)Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)Uyama, T., et al. Biochim. Biophys. Acta 1791(12):1114-1124(2009)Talmud, P.J., et al. Am. J. Hum. Genet. 85(5):628-642(2009)Higuchi, E., et al. Oncogene 22(30):4627-4635(2003)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
